Status:
COMPLETED
GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures
Lead Sponsor:
VA Office of Research and Development
Conditions:
Parkinson's Disease
Eligibility:
All Genders
35+ years
Phase:
NA
Brief Summary
Inflammation plays a central role in Parkinson's disease. The use of anti-inflammatory drugs was found to reduce the risk of PD . Niacin may play an important role in reducing inflammation in PD. The ...
Detailed Description
Inflammation plays a central role in Parkinson's disease (PD) pathology \[1\] as evidenced by the presence of microglia in the substantia nigra in post-mortem samples \[2\] as well as activated microg...
Eligibility Criteria
Inclusion
- PD subjects will be adult men and women diagnosed with idiopathic mild to moderately severe PD defined as modified Hoehn \& Yahr Stages I-III (while "On").
- PD is defined according to the United Kingdom Brain Bank Criteria made at least six months prior to recruitment to the study.
- PD features include the presence of at least two of the four cardinal clinical manifestations of the disease, which are tremor, rigidity, bradykinesia, and disturbances of posture or gait, without any other known or suspected cause of Parkinsonism.
- Subjects should be stabilized on PD medication for at least 3 months before enrollment into the study.
- Subjects' PD drug prescriptions will not be altered nor withheld during the study, i.e., they will be tested while "On."
- The patient will have signed informed consent.
- Subjects who do not have PD (i.e., healthy or have other medical conditions such as traumatic brain injury (TBI), stroke, or other syndromes in which inflammation plays a role in the condition) will also be recruited as control subjects.
- This will allow us to estimate whether these other conditions show similar or unique inflammatory profile.
Exclusion
- Subjects will be excluded if they had previous brain surgery or other severe neurological problems
- intracerebral hemorrhage
- traumatic brain injury
- central nervous system malignancy
- active central nervous system (CNS) infection
- significant stroke
- Alzheimer disease or any type of implanted stimulator including but not limited to Deep Brain Stimulator (DBS) or pacemaker
- All subjects must be without evidence of dementia, defined as a score \> 24 the Mini-Mental State Examination and able to understand test instructions
- Subjects must not have functional blindness (inability to participate in gait and visuomotor assessments) or lower limb amputation higher than the forefoot or any orthopedic problem that precludes performance of physical tests
- Allergic to niacin
- Significant cardiac, pulmonary, hepatic, gastrointestinal, or renal disease
- e.g., New York Heart Association Class III or IV congestive heart failure
- endocarditis
- pulmonary insufficiency symptomatic at rest or with mild physical exertion
- acute or chronic hepatitis
- renal failure requiring dialysis
- second and third degree atrioventricular block or sick sinus syndrome), or diabetes are also exclusionary factors
Key Trial Info
Start Date :
September 28 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 23 2020
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT03462680
Start Date
September 28 2016
End Date
April 23 2020
Last Update
November 17 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Charlie Norwood VA Medical Center, Augusta, GA
Augusta, Georgia, United States, 30904